Annual CFI
-$420.07 M
-$323.92 M-336.87%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual cash flow from investing activities is -$420.07 million, with the most recent change of -$323.92 million (-336.87%) on September 30, 2024.
- During the last 3 years, ARWR annual CFI has fallen by -$278.39 million (-196.50%).
- ARWR annual CFI is now -3074.85% below its all-time high of $14.12 million, reached on September 30, 2015.
Performance
ARWR Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$222.92 M
-$229.87 M-3307.99%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly cash flow from investing activities is -$222.92 million, with the most recent change of -$229.87 million (-3307.99%) on September 30, 2024.
- Over the past year, ARWR quarterly CFI has increased by +$46.01 million (+17.11%).
- ARWR quarterly CFI is now -443.81% below its all-time high of $64.84 million, reached on December 31, 2023.
Performance
ARWR Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$420.07 M
-$253.43 M-152.08%
September 30, 2024
Summary
- As of February 7, 2025, ARWR TTM cash flow from investing activities is -$420.07 million, with the most recent change of -$253.43 million (-152.08%) on September 30, 2024.
- Over the past year, ARWR TTM CFI has dropped by -$236.58 million (-128.93%).
- ARWR TTM CFI is now -950.73% below its all-time high of $49.38 million, reached on December 31, 2023.
Performance
ARWR TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
ARWR Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -336.9% | +17.1% | -128.9% |
| 3 y3 years | -196.5% | -88.5% | -196.5% |
| 5 y5 years | -779.8% | -88.5% | -196.5% |
ARWR Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7654.7% | at low | -443.8% | +17.1% | -950.7% | at low |
| 5 y | 5-year | -7654.7% | at low | -443.8% | +17.1% | -950.7% | at low |
| alltime | all time | -3074.8% | at low | -443.8% | +17.1% | -950.7% | at low |
Arrowhead Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$420.07 M(+336.9%) | -$222.92 M(-3308.0%) | -$420.07 M(+152.1%) |
| Jun 2024 | - | $6.95 M(-102.6%) | -$166.64 M(-9.2%) |
| Mar 2024 | - | -$268.94 M(-514.8%) | -$183.49 M(-471.6%) |
| Dec 2023 | - | $64.84 M(+112.5%) | $49.38 M(-151.4%) |
| Sep 2023 | -$96.16 M(+1675.1%) | $30.51 M(-408.0%) | -$96.16 M(+6.6%) |
| Jun 2023 | - | -$9.90 M(-72.5%) | -$90.22 M(+373.9%) |
| Mar 2023 | - | -$36.06 M(-55.3%) | -$19.04 M(-63.9%) |
| Dec 2022 | - | -$80.69 M(-321.4%) | -$52.73 M(+873.3%) |
| Sep 2022 | -$5.42 M(-96.2%) | $36.45 M(-40.5%) | -$5.42 M(-96.6%) |
| Jun 2022 | - | $61.28 M(-187.8%) | -$160.11 M(-33.5%) |
| Mar 2022 | - | -$69.75 M(+108.9%) | -$240.93 M(+17.4%) |
| Dec 2021 | - | -$33.38 M(-71.8%) | -$205.22 M(+44.9%) |
| Sep 2021 | -$141.68 M(-41.2%) | -$118.25 M(+505.1%) | -$141.68 M(+58.6%) |
| Jun 2021 | - | -$19.54 M(-42.6%) | -$89.33 M(+17.8%) |
| Mar 2021 | - | -$34.05 M(-212.9%) | -$75.82 M(-65.5%) |
| Dec 2020 | - | $30.16 M(-145.8%) | -$219.90 M(-8.7%) |
| Sep 2020 | -$240.78 M(+404.3%) | -$65.89 M(+992.1%) | -$240.78 M(+52.3%) |
| Jun 2020 | - | -$6.03 M(-96.6%) | -$158.05 M(+14.8%) |
| Mar 2020 | - | -$178.13 M(-2019.5%) | -$137.62 M(-569.9%) |
| Dec 2019 | - | $9.28 M(-44.9%) | $29.29 M(-161.3%) |
| Sep 2019 | -$47.75 M(+542.2%) | $16.83 M(+16.9%) | -$47.75 M(-22.1%) |
| Jun 2019 | - | $14.40 M(-228.4%) | -$61.33 M(-41.4%) |
| Mar 2019 | - | -$11.22 M(-83.4%) | -$104.58 M(+36.6%) |
| Dec 2018 | - | -$67.76 M(-2186.7%) | -$76.55 M(+929.6%) |
| Sep 2018 | -$7.43 M(-84.7%) | $3.25 M(-111.3%) | -$7.43 M(-50.1%) |
| Jun 2018 | - | -$28.85 M(-271.6%) | -$14.90 M(-1549.9%) |
| Mar 2018 | - | $16.82 M(+1139.2%) | $1.03 M(-102.4%) |
| Dec 2017 | - | $1.36 M(-132.2%) | -$41.99 M(-13.7%) |
| Sep 2017 | -$48.64 M(-461.7%) | -$4.22 M(-67.4%) | -$48.64 M(+5.4%) |
| Jun 2017 | - | -$12.93 M(-50.7%) | -$46.14 M(+94.3%) |
| Mar 2017 | - | -$26.20 M(+394.7%) | -$23.75 M(-527.4%) |
| Dec 2016 | - | -$5.30 M(+209.3%) | $5.56 M(-58.7%) |
| Sep 2016 | $13.45 M(-4.8%) | -$1.71 M(-118.1%) | $13.45 M(-36.0%) |
| Jun 2016 | - | $9.46 M(+204.6%) | $21.01 M(+35.3%) |
| Mar 2016 | - | $3.11 M(+19.8%) | $15.52 M(-26.8%) |
| Dec 2015 | - | $2.59 M(-55.6%) | $21.21 M(+50.2%) |
| Sep 2015 | $14.12 M(-138.7%) | $5.84 M(+47.0%) | $14.12 M(+10.1%) |
| Jun 2015 | - | $3.98 M(-54.8%) | $12.82 M(+31.1%) |
| Mar 2015 | - | $8.80 M(-295.5%) | $9.78 M(-137.9%) |
| Dec 2014 | - | -$4.50 M(-199.0%) | -$25.84 M(-29.2%) |
| Sep 2014 | -$36.48 M(+283.2%) | $4.54 M(+385.4%) | -$36.48 M(-23.3%) |
| Jun 2014 | - | $936.40 K(-103.5%) | -$47.55 M(-9.8%) |
| Mar 2014 | - | -$26.82 M(+77.1%) | -$52.74 M(+112.9%) |
| Dec 2013 | - | -$15.15 M(+132.3%) | -$24.78 M(+160.3%) |
| Sep 2013 | -$9.52 M(-2260.9%) | -$6.52 M(+53.1%) | -$9.52 M(+237.4%) |
| Jun 2013 | - | -$4.26 M(-471.5%) | -$2.82 M(-307.4%) |
| Mar 2013 | - | $1.15 M(+923.4%) | $1.36 M(>+9900.0%) |
| Dec 2012 | - | $112.00 K(-37.2%) | $13.00 K(-97.0%) |
| Sep 2012 | $440.60 K | $178.40 K(-334.4%) | $440.60 K(-33.9%) |
| Jun 2012 | - | -$76.10 K(-62.2%) | $666.60 K(-47.9%) |
| Mar 2012 | - | -$201.30 K(-137.3%) | $1.28 M(+251.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | $539.60 K(+33.4%) | $364.20 K(-307.6%) |
| Sep 2011 | -$175.40 K(-136.0%) | $404.40 K(-24.7%) | -$175.40 K(-66.4%) |
| Jun 2011 | - | $536.80 K(-148.1%) | -$522.20 K(-50.7%) |
| Mar 2011 | - | -$1.12 M(<-9900.0%) | -$1.06 M(-1938.5%) |
| Dec 2010 | - | $0.00(-100.0%) | $57.60 K(-88.2%) |
| Sep 2010 | $487.60 K(-34.0%) | $57.60 K(>+9900.0%) | $487.60 K(+20.0%) |
| Jun 2010 | - | $0.00(0.0%) | $406.40 K(-9.0%) |
| Mar 2010 | - | $0.00(-100.0%) | $446.70 K(-10.2%) |
| Dec 2009 | - | $430.00 K(-1922.0%) | $497.30 K(-32.7%) |
| Sep 2009 | $739.10 K(-128.7%) | -$23.60 K(-158.6%) | $739.20 K(-107.1%) |
| Jun 2009 | - | $40.30 K(-20.4%) | -$10.43 M(+22.5%) |
| Mar 2009 | - | $50.60 K(-92.5%) | -$8.51 M(-2.7%) |
| Dec 2008 | - | $671.90 K(-106.0%) | -$8.75 M(+239.8%) |
| Sep 2008 | -$2.57 M(-158.8%) | -$11.19 M(-672.0%) | -$2.57 M(-130.6%) |
| Jun 2008 | - | $1.96 M(-1141.0%) | $8.42 M(+39.1%) |
| Mar 2008 | - | -$187.90 K(-102.7%) | $6.05 M(-2.4%) |
| Dec 2007 | - | $6.85 M(-3652.7%) | $6.21 M(+41.7%) |
| Sep 2007 | $4.38 M(-908.1%) | -$192.70 K(-53.1%) | $4.38 M(-76.0%) |
| Jun 2007 | - | -$410.60 K(+992.0%) | $18.26 M(-21.4%) |
| Mar 2007 | - | -$37.60 K(-100.7%) | $23.25 M(+399.4%) |
| Dec 2006 | - | $5.02 M(-63.3%) | $4.66 M(-958.9%) |
| Sep 2006 | -$542.00 K(-123.9%) | $13.69 M(+199.2%) | -$542.10 K(-96.2%) |
| Jun 2006 | - | $4.58 M(-124.6%) | -$14.34 M(-25.0%) |
| Mar 2006 | - | -$18.63 M(>+9900.0%) | -$19.12 M(-970.5%) |
| Dec 2005 | - | -$177.20 K(+72.7%) | $2.20 M(-3.2%) |
| Sep 2005 | $2.27 M(-731.1%) | -$102.60 K(-50.8%) | $2.27 M(+17.7%) |
| Jun 2005 | - | -$208.60 K(-107.8%) | $1.93 M(-13.5%) |
| Mar 2005 | - | $2.69 M(-2664.7%) | $2.23 M(-580.1%) |
| Dec 2004 | - | -$104.70 K(-76.4%) | -$464.30 K(+29.1%) |
| Sep 2004 | -$359.60 K(>+9900.0%) | -$443.50 K(-582.1%) | -$359.60 K(-539.6%) |
| Jun 2004 | - | $92.00 K(-1235.8%) | $81.80 K(-902.0%) |
| Mar 2004 | - | -$8100.00(<-9900.0%) | -$10.20 K(+385.7%) |
| Dec 2003 | - | $0.00(-100.0%) | -$2100.00(0.0%) |
| Sep 2003 | -$2100.00(+23.5%) | -$2100.00(<-9900.0%) | -$2100.00(<-9900.0%) |
| Jun 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2003 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2002 | - | $0.00(0.0%) | -$1700.00(0.0%) |
| Sep 2002 | -$1700.00(<-9900.0%) | $0.00(0.0%) | -$1700.00(0.0%) |
| Jun 2002 | - | $0.00(-100.0%) | -$1700.00(0.0%) |
| Mar 2002 | - | -$1700.00(<-9900.0%) | -$1700.00(<-9900.0%) |
| Dec 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2001 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2000 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Sep 2000 | -$700.00(<-9900.0%) | $0.00(0.0%) | -$700.00(0.0%) |
| Jun 2000 | - | $0.00(0.0%) | -$700.00(0.0%) |
| Mar 2000 | - | $0.00(-100.0%) | -$700.00(0.0%) |
| Dec 1999 | - | -$700.00 | -$700.00 |
| Sep 1999 | $0.00(0.0%) | - | - |
| Sep 1998 | $0.00(0.0%) | - | - |
| Sep 1997 | $0.00 | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual CFI year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly CFI year-on-year change?
- What is Arrowhead Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM CFI year-on-year change?
What is Arrowhead Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of ARWR is -$420.07 M
What is the all time high annual CFI for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash flow from investing activities is $14.12 M
What is Arrowhead Pharmaceuticals annual CFI year-on-year change?
Over the past year, ARWR annual cash flow from investing activities has changed by -$323.92 M (-336.87%)
What is Arrowhead Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of ARWR is -$222.92 M
What is the all time high quarterly CFI for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash flow from investing activities is $64.84 M
What is Arrowhead Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, ARWR quarterly cash flow from investing activities has changed by +$46.01 M (+17.11%)
What is Arrowhead Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of ARWR is -$420.07 M
What is the all time high TTM CFI for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM cash flow from investing activities is $49.38 M
What is Arrowhead Pharmaceuticals TTM CFI year-on-year change?
Over the past year, ARWR TTM cash flow from investing activities has changed by -$236.58 M (-128.93%)